Therapies for active rheumatoid arthritis after methotrexate failure

James Robert O'Dell, Ted R Mikuls, Thomas H. Taylor, Vandana Ahluwalia, Mary Brophy, Stuart R. Warren, Robert A. Lew, Amy C Cannella, Gary Kunkel, Ciaran S. Phibbs, Aslam H. Anis, Sarah Leatherman, Edward Keystone

Research output: Contribution to journalArticle

210 Citations (Scopus)

Abstract

Background: Few blinded trials have compared conventional therapy consisting of a combination of disease-modifying antirheumatic drugs with biologic agents in patients with rheumatoid arthritis who have active disease despite treatment with methotrexate - a common scenario in the management of rheumatoid arthritis. Methods: We conducted a 48-week, double-blind, noninferiority trial in which we randomly assigned 353 participants with rheumatoid arthritis who had active disease despite methotrexate therapy to a triple regimen of disease-modifying antirheumatic drugs (methotrexate, sulfasalazine, and hydroxychloroquine) or etanercept plus methotrexate. Patients who did not have an improvement at 24 weeks according to a prespecified threshold were switched in a blinded fashion to the other therapy. The primary outcome was improvement in the Disease Activity Score for 28-joint counts (DAS28, with scores ranging from 2 to 10 and higher scores indicating more disease activity) at week 48. Results: Both groups had significant improvement over the course of the first 24 weeks (P = 0.001 for the comparison with baseline). A total of 27% of participants in each group required a switch in treatment at 24 weeks. Participants in both groups who switched therapies had improvement after switching (P<0.001), and the response after switching did not differ significantly between the two groups (P = 0.08). The change between baseline and 48 weeks in the DAS28 was similar in the two groups (-2.1 with triple therapy and -2.3 with etanercept and methotrexate, P = 0.26); triple therapy was noninferior to etanercept and methotrexate, since the 95% upper confidence limit of 0.41 for the difference in change in DAS28 was below the margin for noninferiority of 0.6 (P = 0.002). There were no significant between-group differences in secondary outcomes, including radiographic progression, pain, and healthrelated quality of life, or in major adverse events associated with the medications. Conclusions: With respect to clinical benefit, triple therapy, with sulfasalazine and hydroxychloroquine added to methotrexate, was noninferior to etanercept plus methotrexate in patients with rheumatoid arthritis who had active disease despite methotrexate therapy.

Original languageEnglish (US)
Pages (from-to)307-318
Number of pages12
JournalNew England Journal of Medicine
Volume369
Issue number4
DOIs
StatePublished - Jan 1 2013

Fingerprint

Methotrexate
Rheumatoid Arthritis
Hydroxychloroquine
Therapeutics
Sulfasalazine
Antirheumatic Agents
Biological Factors
Joints
Quality of Life
Pain
Etanercept

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Therapies for active rheumatoid arthritis after methotrexate failure. / O'Dell, James Robert; Mikuls, Ted R; Taylor, Thomas H.; Ahluwalia, Vandana; Brophy, Mary; Warren, Stuart R.; Lew, Robert A.; Cannella, Amy C; Kunkel, Gary; Phibbs, Ciaran S.; Anis, Aslam H.; Leatherman, Sarah; Keystone, Edward.

In: New England Journal of Medicine, Vol. 369, No. 4, 01.01.2013, p. 307-318.

Research output: Contribution to journalArticle

O'Dell, JR, Mikuls, TR, Taylor, TH, Ahluwalia, V, Brophy, M, Warren, SR, Lew, RA, Cannella, AC, Kunkel, G, Phibbs, CS, Anis, AH, Leatherman, S & Keystone, E 2013, 'Therapies for active rheumatoid arthritis after methotrexate failure', New England Journal of Medicine, vol. 369, no. 4, pp. 307-318. https://doi.org/10.1056/NEJMoa1303006
O'Dell, James Robert ; Mikuls, Ted R ; Taylor, Thomas H. ; Ahluwalia, Vandana ; Brophy, Mary ; Warren, Stuart R. ; Lew, Robert A. ; Cannella, Amy C ; Kunkel, Gary ; Phibbs, Ciaran S. ; Anis, Aslam H. ; Leatherman, Sarah ; Keystone, Edward. / Therapies for active rheumatoid arthritis after methotrexate failure. In: New England Journal of Medicine. 2013 ; Vol. 369, No. 4. pp. 307-318.
@article{24452640194d44e0a891fd40ed7055fc,
title = "Therapies for active rheumatoid arthritis after methotrexate failure",
abstract = "Background: Few blinded trials have compared conventional therapy consisting of a combination of disease-modifying antirheumatic drugs with biologic agents in patients with rheumatoid arthritis who have active disease despite treatment with methotrexate - a common scenario in the management of rheumatoid arthritis. Methods: We conducted a 48-week, double-blind, noninferiority trial in which we randomly assigned 353 participants with rheumatoid arthritis who had active disease despite methotrexate therapy to a triple regimen of disease-modifying antirheumatic drugs (methotrexate, sulfasalazine, and hydroxychloroquine) or etanercept plus methotrexate. Patients who did not have an improvement at 24 weeks according to a prespecified threshold were switched in a blinded fashion to the other therapy. The primary outcome was improvement in the Disease Activity Score for 28-joint counts (DAS28, with scores ranging from 2 to 10 and higher scores indicating more disease activity) at week 48. Results: Both groups had significant improvement over the course of the first 24 weeks (P = 0.001 for the comparison with baseline). A total of 27{\%} of participants in each group required a switch in treatment at 24 weeks. Participants in both groups who switched therapies had improvement after switching (P<0.001), and the response after switching did not differ significantly between the two groups (P = 0.08). The change between baseline and 48 weeks in the DAS28 was similar in the two groups (-2.1 with triple therapy and -2.3 with etanercept and methotrexate, P = 0.26); triple therapy was noninferior to etanercept and methotrexate, since the 95{\%} upper confidence limit of 0.41 for the difference in change in DAS28 was below the margin for noninferiority of 0.6 (P = 0.002). There were no significant between-group differences in secondary outcomes, including radiographic progression, pain, and healthrelated quality of life, or in major adverse events associated with the medications. Conclusions: With respect to clinical benefit, triple therapy, with sulfasalazine and hydroxychloroquine added to methotrexate, was noninferior to etanercept plus methotrexate in patients with rheumatoid arthritis who had active disease despite methotrexate therapy.",
author = "O'Dell, {James Robert} and Mikuls, {Ted R} and Taylor, {Thomas H.} and Vandana Ahluwalia and Mary Brophy and Warren, {Stuart R.} and Lew, {Robert A.} and Cannella, {Amy C} and Gary Kunkel and Phibbs, {Ciaran S.} and Anis, {Aslam H.} and Sarah Leatherman and Edward Keystone",
year = "2013",
month = "1",
day = "1",
doi = "10.1056/NEJMoa1303006",
language = "English (US)",
volume = "369",
pages = "307--318",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "4",

}

TY - JOUR

T1 - Therapies for active rheumatoid arthritis after methotrexate failure

AU - O'Dell, James Robert

AU - Mikuls, Ted R

AU - Taylor, Thomas H.

AU - Ahluwalia, Vandana

AU - Brophy, Mary

AU - Warren, Stuart R.

AU - Lew, Robert A.

AU - Cannella, Amy C

AU - Kunkel, Gary

AU - Phibbs, Ciaran S.

AU - Anis, Aslam H.

AU - Leatherman, Sarah

AU - Keystone, Edward

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Background: Few blinded trials have compared conventional therapy consisting of a combination of disease-modifying antirheumatic drugs with biologic agents in patients with rheumatoid arthritis who have active disease despite treatment with methotrexate - a common scenario in the management of rheumatoid arthritis. Methods: We conducted a 48-week, double-blind, noninferiority trial in which we randomly assigned 353 participants with rheumatoid arthritis who had active disease despite methotrexate therapy to a triple regimen of disease-modifying antirheumatic drugs (methotrexate, sulfasalazine, and hydroxychloroquine) or etanercept plus methotrexate. Patients who did not have an improvement at 24 weeks according to a prespecified threshold were switched in a blinded fashion to the other therapy. The primary outcome was improvement in the Disease Activity Score for 28-joint counts (DAS28, with scores ranging from 2 to 10 and higher scores indicating more disease activity) at week 48. Results: Both groups had significant improvement over the course of the first 24 weeks (P = 0.001 for the comparison with baseline). A total of 27% of participants in each group required a switch in treatment at 24 weeks. Participants in both groups who switched therapies had improvement after switching (P<0.001), and the response after switching did not differ significantly between the two groups (P = 0.08). The change between baseline and 48 weeks in the DAS28 was similar in the two groups (-2.1 with triple therapy and -2.3 with etanercept and methotrexate, P = 0.26); triple therapy was noninferior to etanercept and methotrexate, since the 95% upper confidence limit of 0.41 for the difference in change in DAS28 was below the margin for noninferiority of 0.6 (P = 0.002). There were no significant between-group differences in secondary outcomes, including radiographic progression, pain, and healthrelated quality of life, or in major adverse events associated with the medications. Conclusions: With respect to clinical benefit, triple therapy, with sulfasalazine and hydroxychloroquine added to methotrexate, was noninferior to etanercept plus methotrexate in patients with rheumatoid arthritis who had active disease despite methotrexate therapy.

AB - Background: Few blinded trials have compared conventional therapy consisting of a combination of disease-modifying antirheumatic drugs with biologic agents in patients with rheumatoid arthritis who have active disease despite treatment with methotrexate - a common scenario in the management of rheumatoid arthritis. Methods: We conducted a 48-week, double-blind, noninferiority trial in which we randomly assigned 353 participants with rheumatoid arthritis who had active disease despite methotrexate therapy to a triple regimen of disease-modifying antirheumatic drugs (methotrexate, sulfasalazine, and hydroxychloroquine) or etanercept plus methotrexate. Patients who did not have an improvement at 24 weeks according to a prespecified threshold were switched in a blinded fashion to the other therapy. The primary outcome was improvement in the Disease Activity Score for 28-joint counts (DAS28, with scores ranging from 2 to 10 and higher scores indicating more disease activity) at week 48. Results: Both groups had significant improvement over the course of the first 24 weeks (P = 0.001 for the comparison with baseline). A total of 27% of participants in each group required a switch in treatment at 24 weeks. Participants in both groups who switched therapies had improvement after switching (P<0.001), and the response after switching did not differ significantly between the two groups (P = 0.08). The change between baseline and 48 weeks in the DAS28 was similar in the two groups (-2.1 with triple therapy and -2.3 with etanercept and methotrexate, P = 0.26); triple therapy was noninferior to etanercept and methotrexate, since the 95% upper confidence limit of 0.41 for the difference in change in DAS28 was below the margin for noninferiority of 0.6 (P = 0.002). There were no significant between-group differences in secondary outcomes, including radiographic progression, pain, and healthrelated quality of life, or in major adverse events associated with the medications. Conclusions: With respect to clinical benefit, triple therapy, with sulfasalazine and hydroxychloroquine added to methotrexate, was noninferior to etanercept plus methotrexate in patients with rheumatoid arthritis who had active disease despite methotrexate therapy.

UR - http://www.scopus.com/inward/record.url?scp=84880753128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880753128&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1303006

DO - 10.1056/NEJMoa1303006

M3 - Article

VL - 369

SP - 307

EP - 318

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 4

ER -